{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006292","form_type":"8-K","ticker":"TCMD","cik":"0001027838","company_name":"TACTILE SYSTEMS TECHNOLOGY INC","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.190895+00:00","generated_at":"2026-05-22T16:12:47.149097+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tactile Medical Q1 revenue flat, net loss widens; lowers FY 2025 revenue and EBITDA guidance","bullets":["Q1 2025 revenue $61.3M (+0.3% YoY); net loss $3.0M vs $2.2M loss in Q1 2024.","Adjusted EBITDA loss $0.3M vs positive $1.0M in prior-year quarter.","Lymphedema product sales -3% YoY; airway clearance +22% YoY.","FY 2025 revenue guidance lowered to $309-315M (prior $316-322M); EBITDA guidance cut to $32-34M from $35-37M.","Repurchased $10M of stock in Q1; $16.5M remaining under $30M buyback program."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006292","json":"https://secwatch.observer/filing/0001558370-25-006292.json","markdown":"https://secwatch.observer/filing/0001558370-25-006292.md","text":"https://secwatch.observer/filing/0001558370-25-006292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1027838/000155837025006292/0001558370-25-006292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1027838/000155837025006292/tcmd-20250505x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:12:47.149097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}